A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

NCT03653247 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

BIOLOGICAL: Plerixafor
DRUG: Busulfan
GENETIC: BIVV003

Sponsor

Sangamo Therapeutics